Back to results
US 2014/0155397 A1Published application
Emt signatures and predictive markers and method of using the same
AssigneeBoard of Regents
InventorsJohn V Heymach, Jing Wang, Lauren Averett Byers, Kevin R. Coombes, John D. Minna, Luc Girard
Life of this patent
Estimating the term…
Abstract
EMT signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.
Claims20
-7. (canceled)
A method for classifying an EMT status of a patient with non-small-cell lung cancer (NSCLC) comprising:
- (a) obtaining a sample of the cancer;
- (b) detecting an expression level in the sample of at least two nucleic acid molecules selected from the group consisting of the genes listed in Table 1;
- and
- (c) comparing the expression level of the at least two nucleic acid molecules to a control level indicative of a known EMT status, wherein the comparison permits classifying the EMT status of the non-small-cell lung cancer in the patient as epithelial-like or mesenchymal-like.
1 more element
A method of treating a patient with NSCLC comprising:
- (a) obtaining a sample of the cancer;
- (b) detecting an expression level in the sample of at least one gene selected from the group consisting of:
- NPR3, C4orf23, LCN2, OGG1, and TRIM72;
- (c) comparing the expression level of the at least one gene to a control level indicative of EGFR inhibitor sensitivity, thereby classifying NSCLC as EGFR inhibitor sensitive or resistant;
- and
- (d) administering a therapeutically effective amount of an EGFR inhibitor to the patient if the NSCLC is classified as EGFR inhibitor sensitive.
3 more elements
Dependencies are inferred from the claim text.